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Abstract
Background: The incidence of molar pregnancy has demonstrated marked geographic and ethnic differences. The
reported data in Nepal is inconsistent with minimal published literature. Thus, we designed a study to determine
prevalence of molar pregnancies and demonstrate clinical and epidemiological characteristics of the patients
attending a tertiary care center in eastern Nepal.
Methods: A retrospective review of medical records was conducted to determine the prevalence of molar
pregnancies at the B.P. Koirala Institute of Health Sciences (BPKIHS) from the year 2008 to 2012. Secondary data
from the medical records were analyzed. Annual and 5-year prevalence of molar pregnancy per 1000 live births
was calculated. Demographic characteristics, clinical presentation, management methods and complications of
molar pregnancy were studied.
Results: The 5- year prevalence of molar pregnancy at BPKIHS is 4.17 per 1000 live births with annual prevalence
ranging 3.8–4.5 per 1000 live births. More than one third of the patients were in the age group of 20–35 years
and majority of them were of Hindu religion. For more than one third (41.7 %) of the patients, it was their first
pregnancy while about 10 % gave a positive past history of molar pregnancy. Abnormal uterine bleeding (86.3 %)
was the most frequent complaint, suction evacuation was the most common method of treatment and more
than half of the patients required prolonged care after initial management.
Conclusion: There is a need for studies at country level which will give us a national figure on molar pregnancies.
Thus, a standardized clinic-epidemiological profile of molar pregnancy in Nepal can be created.
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Background
The management of gestational trophoblastic disease
(GTD) depicts one of the success stories of modern medi-
cine. As the majority, if not all, GTDs are potentially
curable with the retention of reproductive function, once
the correct diagnosis is made and treatment is com-
menced early enough [1–4] GTD constitutes a spectrum
of tumors and tumor-like conditions characterized by
abnormal proliferation of pregnancy associated tropho-
blastic tissues of varying propensities for invasion and
spread [4–7].
They include complete and partial hydatidiform mole,
invasive mole, placental-site trophoblastic tumor (PSTT),
and choriocarcinoma. Hydatidiform mole is the most
common GTD [5, 7].
The incidence of GTD varies greatly in different parts
of the world, with 0.4 per 1000 birth in United States of
America to 12.5 per 1000 births in Taiwan [8]. In Nepal,
hospitals in Kathmandu valley have recorded its inci-
dence as 5.1, 2.9, 2.8, and 4.1 per 1000 live births [9].
These 10–20‐fold variations in the incidence of molar
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pregnancy might be overestimated by reporting biases,
such as population‐based and hospital‐based data [2].
Published literature on incidence of hydatidiform mole
from this part of the world is rather minimal.
Maternal age is the most consistent risk factor for
GTD in geographical regions and ethnic groups. Com-
monly affecting women in the reproductive age group,
GTD has the propensity to become malignant but rela-
tively easy to identify, diagnose and treat. Clinically
hydatidiform mole presents with amenorrhoea, painless
vaginal bleeding and spontaneous passage of grape-like
vesicles, high serum and urinary β human chorionic
gonadotrophin (βHCG) levels. There may also be hyper-
emesis gravidarum, doughy uterus, inappropriate uter-
ine size, bilateral theca lutein cyst and rarely, features
of thyrotoxicosis and pre-eclampsia in the first half of
pregnancy [10–12]. Hydatidiform mole is a relatively
common gynecological problem which could present
like spontaneous abortion, one of the most common
gynecological emergencies. Ultrasonography is a simple
non-invasive examination which can correctly identify
the placental molar transformations in-utero. Currently
with widespread use of first trimester ultrasonography a
significant proportion of patients with molar pregnancy
are asymptomatic at the time of diagnosis. Careful and
reliable human chorionic gonadotropin monitoring is
essential for the early detection of post molar persistent
gestational trophoblastic tumor.
Studies concerning the epidemiological characteristics,
clinical presentation, management practices and out-
come of molar pregnancy are rarely published from
Nepal apart from a few case reports. Considering the
relative lack of published epidemiology studies on hyda-
tidiform mole from Nepal and considering the varied
incidence rates reported from Asian countries, there is a
need to determine the incidence rate in eastern Nepalese
population in a well designed epidemiological study.
With this background, we analyzed the past medical
records of 5 years to determine the prevalence of molar
pregnancy, evaluate the management practices and
determine the outcome of hydatidiform mole at B P
Koirala Institute of Health Sciences (BPKIHS), a ter-
tiary care centre in eastern part of Nepal.
Methods
A retrospective review of medical records was conducted at
B. P. Koirala Institute of Health Sciences (BPKIHS) to de-
velop a clinio—epidmiological profile of molar pregnancy.
All women who are diagnosed with molar pregnancy/
hydatidiform mole (complete or partial) sonologically or
histopathologically, and reporting to BPKIHS for treatment
during the study period i.e. between 2008–2012 were in-
cluded in the study. The data for total deliveries conducted
in the hospital during the study period was also taken from
the hospital registries. In-patient medical records from the
medical records section of BPKIHS from the year 2008 to
2012 were reviewed and information of the current study
was acquired.
The current study was approved by the Institutional
Ethical Review Board (IERB), BPKIHS. Permission from
the Hospital authority was taken to access the medical
records was taken. All information collected from the
hospital records were kept confidential. The details of
maternal characteristics like maternal age, parity and
period of gestation at the time of presentation, clinical
presentation, diagnostic tools, management and complica-
tions was noted for each of cases. Details of past obstetric
history such as previous history of molar pregnancy was
noted as well as complications of molar pregnancy occur-
ring during the hospital stay, need for blood transfusion
or intensive care unit stay was noted. Anemia is classified
according to the WHO criteria for anemia during preg-
nancy [13].
Descriptive statistics were used to summarize the con-
tinuous and categorical variables. Period prevalence was
calculated by the number of cases of molar pregnancies
reported to the institution for treatment during the
study period for every 1000 live births delivered during
the same period. All statistical analyses were performed
using SPSS version 11.5.
Results
A total of 48,805 live births took place in BPKIHS dur-
ing from 2008 and 2012 with 204 molar pregnancies.
The 5- year prevalence of molar pregnancy at BPKIHS is
4.17 per 1000 live births. The annual prevalence of
molar pregnancies during the study period ranged from
3.8–4.5 per 1000 live births as shown in Table 1.
Table 2 shows the clinical profile of the patients
reporting to BPKIHS for treatment of molar pregnancy.
A total of 204 cases of molar pregnancy were included
in this study. More than one third of the patients were in
the age group of 20–35 years with a range of 16–51 and
mean age 23.9 years. Majority of the patients belonged to
Hindu religion. More than one third (41.7 %) of the pa-
tients were primigravida and about ten per cent gave a
positive past history of molar pregnancy. The period of
gestation ranged from 8 to 34 weeks with a major propor-
tion (66.4 %) having period of gestation more or equal to
13 weeks with average uterine height of 17.8 weeks. About
a quarter (24.5 %) of the patients gave a positive history of
contraceptives with injectables (66 %) being the most fre-
quently used followed by oral contraceptives (26 %). More
than one third (38.7 %) of patients had pallor on examin-
ation. The Ultra-sonography (USG) findings suggest that
more than one fifth (20.6 %) of pregnant women had theca
lutein cysts. The blood grouping found A positive to be
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the most common blood group followed by O positive
and B positive.
The hCG level of patients on an average was
18644.70 IU/ml while post management during the fol-
low up after 1 week was 4156.84 IU/ml.
There were 28 (13.7 %) patients who had come to our
hospital for regular ANC checkup, who were later diag-
nosed molar pregnancy. The rest 176 (86.3 %) cases pre-
sented with one or more complaints. Abnormal uterine
bleeding (86.3 %) was the most frequent complaint of
the patients coming to our center with molar pregnancy
followed by, pain per abdomen (33.8 %), hyper emesis
(26.5 %) and passage of grape like cysts (11.8 %). The
various treatment modalities for molar pregnancy were
Table 1 Prevalence of molar pregnancy per 100 live births at
BPKIHS, Nepal








2008 38 18.6 8976 4.2/1000
2009 38 18.6 9866 3.8/1000
2010 42 20.6 10234 4.1/1000
2011 44 21.6 9651 4.6/1000
2012 42 20.6 10078 4.2/1000
Total 204 100.0 48805 4.2/1000
Table 2 Clinico-epidemiological profile of patients with molar pregnancy attending BPKIHS, Nepal
Variables Categories Number Percentage
Age group in years ≤20 51 25.0 %
20–35 143 70.1 %
≥35 10 04.9 %
Mean age ± sd = 23.9 ± 6.6 Range = 16–51 years
Religion Hindu 174 85.8 %
Kirat 24 11.8 %
Buddhist 03 01.5 %
Muslim 02 01.0 %
Parity Primigravida 85 41.7 %
Multigravida 119 58.3 %
Previous history of molar pregnancy Yes 18 08.8 %
No 186 91.2 %
Period of gestation ≥13 weeks 131 64.2 %
<13 weeks 73 35.8 %
Period of gestation (in weeks) Mean age ± sd = 15.9 ± 5.8 weeks; Range = 6–34 weeks
Previous history of contraceptive usage Yes 50 24.5 %
No 154 75.5 %
Type of contraceptive use Oral contraceptives 13 26.0 %
Injectable (Depo) 33 66.0 %
IUCD (Copper-T) 03 06.0 %
Intra dermal patch(Norplant) 01 02.0 %
Mean ± Sd (uterine size in weeks) 17.8 ± 6.5 weeks; Range: 06–36 weeks
Pallor Presence 79 38.7 %
Absence 125 61.3 %
Theca lutein cyst on USG Presence 42 20.6 %
Absence 162 79.4 %
Blood group A positive 80 39.2 %
O positive 63 30.9 %
B positive 52 25.5 %
AB positive 07 03.4 %
B negative 02 01.0 %
Agrawal et al. Gynecologic Oncology Research and Practice  (2015) 2:9 Page 3 of 7
used. Suction evacuation was the most common method
of treatment followed by chemotherapy and manual vac-
uum extraction. Combined treatment modalities were
used among 6.8 % of patients (Table 3).
Table 4 shows that 56.4 % of patients suffered compli-
cations during management of cases. Blood transfusion
was required among 45.6 % of patients, and anemia was
seen among 40.2 % of the patients. There were 11.8 %
were admitted in Intensive Care Unit (ICU) for post
management care, fever was seen among 6.4 % of cases
and Gestational Trophoblastic Neoplasia (GTN) was di-
agnosed in 5.9 % of cases.
Discussion
The 5- year prevalence of molar pregnancy at BPKIHS
from 2008–2012 was 4.17 per 1000 live birth with range
of annual prevalence of molar pregnancies during the
study period between 3.85–4.50 per 1000 live births. A
study reports a lower prevalence among Asian popula-
tion of about 2.58 per 1000 live births [14]. As BPKIHS
is the tertiary referral hospital for the whole of Eastern
Nepal, the cases and the deliveries represent a large pro-
portion of cases that show up at a hospital for treatment.
However the prevalence may be different, as deliveries
also happen at home or at birthing centers at govern-
mental and private health institutions in eastern Nepal.
Half of the delivery takes place at home in Nepal [15].
There are wide geographical variations in the inci-
dence of gestational trophoblastic disease as a result of
differences in methodology, classifications of mole, case
detection [14]. Similarly, the epidemiology of tropho-
blastic disease in Nepal remains unknown as there are
inconsistent findings from many centers. A study done
from maternity hospital of Kathmandu reported annual
incidence of 2.84 and 3.24 per 1000 live births while in
another teaching hospital the incidence of trophoblastic
disease ranged from 7.07 per 1000 pregnancies to 8.04
per 1000 deliveries [16]. A study done to compare GTD
among Asian women of North England and North
Wales showed that Asian women are at increased risk of
having molar pregnancies compared to the western pop-
ulations [14].
While in the current study, more than one third of the
patients were in the age group of 20–35 years with a
range of 16–51 and mean age of 23.7 years. Prevalence
of molar pregnancy was found to be higher in women
younger than 29 years (80 %) in another 8 year retro-
spective study done in Kathmanudu [9]. In other studies,
it has been found that there is a relationship between
risk of molar pregnancy and both upper and lower ex-
tremes of maternal age. Furthermore, the extent of risk
is much greater with older rather than younger maternal
ages, and it is only at the true extremes of maternal age
(15 and 45 years) that the increase in risk sharply rises
Table 3 Presenting complaints and subsequent management of molar pregnancies at BPKIHS, Nepal
Symptoms and management Number (n = 204) Percentage (%)
Symptoms (multiple responses) Abnormal uterine bleeding 176 86.3 %
Lower Abdominal Pain 69 33.8 %
Hyperemesis 54 26.5 %
Passage of grape like cysts 24 11.8 %
Hemoptysis 14 06.9 %
Mass per abdomen 08 03.9 %
Shortness of breath 06 02.9 %
Fever 06 02.9 %
Nausea and Vomiting 03 01.5 %
Chest pain 02 01.0 %
Abdominal distension 01 0.5 %
Shock 01 0.5 %
No symptoms 28 13.7 %
Management methods Suction and Evacuation 183 89.8 %
Suction and Evacuation + Chemotherapy 12 5.8 %
Chemotherapy 5 2.4 %
Spontaneous abortion 1 0.5 %
Manual vacuum extraction 1 0.5 %
Suction and Evacuation +Manual Vacuum Extraction 1 0.5 %
Manual vacuum extraction + Chemotherapy 1 0.5 %
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[17]. There is a need to look further about the associ-
ation of age with molar pregnancies in future studies.
More than one third (41.7 %) of the patients were
primigravida and about ten per cent gave a positive past
history of molar pregnancy. In a descriptive case series
from 2001 to 2007 in Bharatpur, Nepal showed that in
15.5 % of cases of molar pregnancy had occurred among
primigravida and same proportion had positive past his-
tory of molar pregnancy [18] while large proportion
(36.7 %) of primigravida suffered from molar pregnancy
in another study [2]. However, studies have also shown
that there is no real association of gravidity with molar
pregnancy when corrected for age [19].
The period of gestation ranged from 8 to 34 weeks with a
major proportion (66.4 %) having gestational age at time of
evaluation more or equal to 13 weeks and the average uter-
ine size at evaluation was 17.83 ± 6.54 weeks in the present
study. A study from Sweden also reported the mean gesta-
tional age at the time of USG was 12.4 weeks similar to our
study [20] while dissimilar findings was seen from the New
England Trophoblastic Disease Centre [21]. According to
their report, the mean estimated gestational age at evalu-
ation was 11.8 weeks (range 6–22) and the mean uterine
size at evaluation was 12.4 weeks (range 7–20 weeks) [21].
The mean level of pre-evacuation hCG of our patients
was 18,644 IU/ml and after the management during the
follow up after 1 week was 4156.84 IU/ml. This level was
much lower compared to an Israeli study which reported
The mean pre-evacuation β-hCG was 2,75,901 IU/l (range
2,011,000–9,19, 000 IU/l) [22]. The analysis of Hungarian
patients in 2004 with uncomplicated hydatidiform mole,
indicates that once undetectable serum hCG levels are
attained relapse is unlikely. The follow up of uncomplicated
partial moles and complete moles with weekly serum hCG
levels until negative titers seems to be safe [23].
The USG findings among patients attending BPKIHS
suggests that more than one fifth (20.6 %) of pregnant
women had theca lutein cyst. USG service is available in
some institutions of eastern Nepal. However, there are
limited places in referral area with reliable recording and
reporting done by ultrasonologists. Similar proportion
(24.5 %) of theca lutein was reported by a study in an-
other region of Nepal [18].
The patients presented to our center with abnormal
uterine bleeding as the most frequent (86.3 %) complaint.
The other presenting symptoms were pain (33.8 %), hyper
emesis (26.5 %) and passage of grape like cysts (11.8 %)
while 13.7 % did not report any symptoms and were diag-
nosed during routine examination. More than one third
(38.7 %) of patients had pallor on examination.
Similar complaints were reported by patients with molar
pregnancies in various studies. Vaginal bleeding was the
most common presenting symptom while presence of ex-
cessive uterine size, anaemia, pre-eclampsia, hyperemesis
and hyperthyroidism was significantly less common
among current patients than in past cases at a centre [21].
A study from Israel showed that although vaginal
bleeding was the most common presenting symptom
while 41 % of their patients were asymptomatic. Further-
more, systemic manifestations such as hyperemesis, pre-
eclampsia, clinical thyrotoxicosis and respiratory distress
were exceedingly rare in this study [22]. It was seen from
reports of a study done in Sweden that the current clin-
ical presentation of complete mole has clearly changed
compared to that of the classic type of mole with vaginal
bleeding (77 %), abdominal pain (23 %) and hyperemesis
(19 %) being the most commonly occurring symptoms.
The clinical presentation of partial moles usually includes
no typical symptoms. Rather, the signs and symptoms are
those of incomplete abortion or missed abortion [23].
In the present study, the various management methods
were suction evacuation, chemotherapy and manual vac-
uum extraction. Combined treatment modalities were
used among 6.8 % of patients. At another center in Nepal,
13.3 % of patients were treated with suction evacuation,
62.2 % of patients underwent adjuvant chemotherapy
among which 26.6 % received single agent chemotherapy
and received EMA-CO regimen [18].
Table 4 Complications (multiple responses) seen during and
after management of molar pregnancies at BPKIHS, Nepal
Complications Number Percentage
Present 115 56.4 %
Absent 89 43.6 %
1. Blood transfusion 93 45.6 %
2. Anemia 82 40.2 %
3. Admission in ICU 24 11.8 %
4. Fever 13 6.4 %
5. Gestational Trophoblastic Neoplasia 12 5.9 %
6. Hemoptysis 10 4.9 %
7. Retain products of conception 06 2.9 %
8. Shortness of breath 05 2.5 %
9. Re-Manual Vaccum Aspiration 05 4.5 %
10. Edema 01 0.5 %
11. High blood pressure 01 0.5 %
12. Intravenous Iron therapy 01 0.5 %
13. Hyperthyroidism 01 0.5 %
14. Upper Respiratory tract Infection 01 0.5 %
15. Rise in Hcg 01 0.5 %
16. Septic abortion 01 0.5 %
17. Glossitis 01 0.5 %
18. Exploratory Laporotomy 01 0.5 %
19. Ventillation support 01 0.5 %
20. Invasive Mole 01 0.5 %
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Gestational Trophoblastic Neoplasia (GTN) was diag-
nosed in 5.9 % of cases the cases could suggest that
there may be over diagnosis of molar pregnancy in this
center. This may need further investigation in the future.
A large proportion (56.4 %) of the patients in this
study required extra attention and suffered some form
(major or minor) complications during management of
cases. This can be due to patients coming with more
severe conditions and complaints in which management
is aggressive and require long term attention and care.
With anemia seen among 40.2 % of the patients, transfu-
sion was done in 45.6 % of the patients. A high level of
is reported by another study [21]. ICU admission and re-
spiratory distress have been reported in other studies
[24–26]. During the management of molar pregnancy, pa-
tients are required to pre arrange blood for transfusion.
While those with anticipated hemorrhage are transfused,
many don’t require transfusion. Admissions in ICU in-
cluded those patients with shortness of breath, septic
abortion, exploratory laporotomy, patient requiring venti-
lation support, and those that are anticipated to required
were kept in Intensive unit for observation for 24 to 48 h.
However, since these are based on the medical records the
practices could not be further explored in detail. There
seems to be a need for a standard protocol for manage-
ment of molar pregnancy in our hospital.
This study used a secondary data source and thus, val-
idity and reliability of the data is of concern. Patients of
molar pregnancy need follow up for at least 9 months,
there was no data on follow up of patients which also an
important issue. The study has limitations of not having
the descriptions of the type of molar pregnancy. The
medical records could not provide the findings dings on
the histopathologic examinations (HPE) which could have
given a more clearepicture molar pregnancy. There is a
need to strengthen the recording and reporting system to
include the comprehensive records in our hospital.
Conclusion
The 5-year prevalence of molar pregnancy at B.P. Koirala
Insitute of Health Sciences—the only tertiary care center of
eastern Nepal during the study period of 2008–2012 is 4.17
per 1000 live births. Similar studies in the future at a na-
tional level will help us to reach a national figure regarding
prevalence and incidence of molar pregnancies in Nepal.
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